JPH0128002B2 - - Google Patents
Info
- Publication number
- JPH0128002B2 JPH0128002B2 JP994081A JP994081A JPH0128002B2 JP H0128002 B2 JPH0128002 B2 JP H0128002B2 JP 994081 A JP994081 A JP 994081A JP 994081 A JP994081 A JP 994081A JP H0128002 B2 JPH0128002 B2 JP H0128002B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- triethylamine
- ester
- skin
- dihydrolipoic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002537 cosmetic Substances 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 239000002253 acid Substances 0.000 description 31
- 235000019136 lipoic acid Nutrition 0.000 description 19
- 229960002663 thioctic acid Drugs 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical class OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 18
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- 125000004494 ethyl ester group Chemical group 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- -1 cetyl ester Chemical class 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000004808 2-ethylhexylester Substances 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- WFSGQBNCVASPMW-UHFFFAOYSA-N 2-ethylhexanoyl chloride Chemical compound CCCCC(CC)C(Cl)=O WFSGQBNCVASPMW-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
- 241001091538 Dimorphandra Group A Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- MOOAHMCRPCTRLV-UHFFFAOYSA-N boron sodium Chemical compound [B].[Na] MOOAHMCRPCTRLV-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000000598 lipoate effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Description
本発明は新規な化粧料、更に詳しくは還元型α
―リポ酸(ジヒドロリポ酸)の誘導体を配合して
なる化粧料に関するものである。
従来、α―リポ酸自体は動植物界で蛋白質に結
合した状態で広く分布し、定性的に検出されてい
る。量的には例えば、動物の肝臓には3.2μg/g
(乾燥重量)程度存在すると云われている。この
α―リポ酸は、ピルピン酸が哺乳動物細胞ミトコ
ンドリア分画中でTCAサイクルに入る際、コエ
ンチームA(以下CoAと略記)の関与の下に酸化
されてアセチルCoA、炭酸ガス、水素2原子に
なる段階において、そのアシル基の転位に関与し
ている。生体内に存在するα―リポ酸はアシル基
がCoASHへ転位後、還元型のジヒドロリポ酸を
形成するが、リポ酸脱水素酵素により再酸化され
α―リポ酸に戻る。このようにα―リポ酸は生体
内で可逆的に酸化還元される物質であり、細胞内
でのエネルギー産生への重要な役割を果している
が、同物質を実用性に留意した形で化粧料へ応用
した公知の例は皆無と云つてよい。その理由は、
α―リポ酸自体が、固体では比較的安定ではある
が、融点以上に加熱したり、または溶液状態では
酸、光などの存在によりS―S結合が解裂し重合
する傾向があり、その安定性に難があるためであ
つた。
本発明者は、前記α―リポ酸の効果的利用につ
いて鋭意研究した結果、その還元型(ジヒドロリ
ポ酸)を誘導体化することにより、上記難点を解
消し、加えて化粧料基剤に配合した場合、皮膚に
塗布した際の効果、すなわちチロシナーゼ活性阻
害に基づく皮膚の色黒やシミ、ソバカスの防止等
の効果がα―リポ酸と比較し著しく向上された化
粧料を見出すに到つた。
一般に皮膚に対して日光からの紫外線が照射さ
れると、皮膚内のチロシナーゼ活性作用により、
メラニンが著しく生成して皮膚が黒化する傾向が
ある。このような皮膚の黒色化現象を防止する物
質としては、かねてよりアスコルビン酸類、過酸
化水素、グルタチオン、ゴロイド硫黄等や各種天
然物が知られているが、アスコルビン酸類は湿性
化粧料の如き水分を多く含む系においては酸化さ
れやすく不安定であり、変色・変臭の原因となり
がちである。過酸化水素については過酸化物と云
う特性上、保存面、安定性面からも充分なものと
は云い難い。グルタチオンやコロイド硫黄は著し
い異臭を放つため化粧料へ使用することは避けら
れている。また、天然物については効果の確認さ
れたものは殆んどなく、しかも前記の各物質と同
様に皮膚に対する効果は充分に満足すべきもので
はない。
すなわち、本発明の主たる目的はジヒドロリポ
酸誘導体を化粧料基剤に配合することにより、従
来公知の物質では得られない極めて優れた特性と
効果を有する新規な化粧料を提供することにあ
る。
本発明に適用されるジヒドロリポ酸誘導体は下
記一般式()で示されるもので、式中6位と8
位のメルカプト基を各種アシル基で置換し、また
カルボキシル基を無置換又は各種アルキル基によ
りエステル化したものである。
一般式()
(式中、Rは直鎖又は分岐脂肪酸アシル残基で
あり、R′は水素原子又は直鎖、分岐アルコール
アルキル残基のいずれかを表わす。)
上記ジヒドロリポ酸誘導体であるS・S―ジア
シルリポ酸及びそのエステル誘導体の具体例とし
ては、S・S―ジブタノイルリポ酸、S・S―ジ
オクタノイルリポ酸、S・S―ジラウロイルリポ
酸、S・S―ジパルミトイルリポ酸、S・S―ジ
―2―エチルヘキサノイルリポ酸、S・S―ジ―
2―ヘキシルデカノイルリポ酸、S・S―ジオク
タノイルリポ酸エチルエステル、S・S―ジパル
ミトイルリポ酸エチルエステル、S・S―ジ―2
―エチルヘキサノイルリポ酸―2―エチルヘキシ
ルエステル、S・S―ジ―2―ヘキシルデカノイ
ルリポ酸オクチルドデシルエステル、S・S―ジ
ラウロイルリポ酸セチルエステル、S・S―ジブ
タノイルリポ酸2―ヘキシルデシルエステルなど
の一般式()の中のRで示されたアシル基が炭
素数2〜20,R′で示されたアルキル基が炭素数
1〜20のものが安定性ならびに化粧料への取り扱
いのしやすさの面から挙げられ、これらは各種化
粧料剤型に応じて適宜選択されるものである。特
に安定性、有効性の点で優れたものとしてS・S
―ジオクタノイルリポ酸エチルエステル、S・S
―ジパルミトイルリポ酸エチルエステル等が挙げ
られる。
本発明に適用されるS・S―ジアシルリポ酸及
びそのアルキルエステル誘導体を合成する方法と
しては種々あるが、例えばS・S―ジアシルリポ
酸においては、α―リポ酸をエタノール等適当溶
媒下で水素化硼素ナトリウムの如き還元剤により
ジスルフイド結合を開裂し、ジヒドロリポ酸とな
し、これにテトラヒドロフラン等非極性溶媒下、
トリエチルアミン等塩基存在下、所望の脂肪酸ク
ロライドを反応させ目的物を得る方法が有利であ
り、またS・S―ジアシルリポ酸アルキルエステ
ル誘導体においては、まずα―リポ酸をクロロホ
ルム等適当溶媒下、トリエチルアミン等塩基存在
下塩化チオニル等塩素化剤を作用させ、α―リポ
酸クロライドを生成せしめ、これにエタノール、
セタノール等所望のアルコールをトリエチルアミ
ン等塩基存在下反応させ、α―リポ酸アルキルエ
ステルとなし、以後ジスルフイド開裂、アシル化
は前記手法に従つて目的物を得る方法が同じく有
利である。
次にS・S―ジアシルリポ酸及びそのアルキル
エステル誘導体の合成例を示す。
合成例1 S・S―ジパルミトイルリポ酸
水素化硼素ナトリウム16gをエタノール200ml
に溶解し、これにα―リポ酸20.6gをエタノール
100mlに溶解した溶液を氷冷下において滴下しな
がら1時間撹拌反応させ、次いで過剰の水素化硼
素ナトリウムを5%塩酸で中和後、生成した粗生
成物を酢酸エチルで抽出し、水洗後、溶媒を40℃
以下で減圧留去し、ジヒドロリポ酸を得る。これ
をテトラヒドロフラン200mlに溶解し、トリエチ
ルアミン32gを加えた混合液に、パルミチン酸ク
ロライド60gを氷冷下において滴下しながら1時
間撹拌反応させ、次いで室温で2時間撹拌後、未
反応パルミチン酸クロライド、トリエチルアミン
をエタノール及び2%塩酸でそれぞれ処理後、反
応物を酢酸エチルで抽出し、さらに抽出溶媒を留
去し粗反応物を得た。精製はカラムを用い、ヘキ
サン/エーテル(98/2)溶媒により溶出させ、
白色結晶のS・S―ジパルミトイルリポ酸45gを
得る。収率66%
元素分析
実測値 C:70.56% H:11.02% O:9.08%
(計算値 C:70.18% H:11.11% O:9.36%)
合成例2 S・S―ジオクタノイルリポ酸エチル
α―リポ酸20.6gとトリエチルアミン10.1gをク
ロロホルム100mlに溶解した混合液に、別に新し
く蒸溜した塩化チオニル11.9gをクロロホルム30
mlに溶解したものを、氷冷下において滴下しなが
ら1時間撹拌反応させ、生成するα―リポ酸クロ
ライドを取り出すことなく、エタノール32gを加
え、トリエチルアミン10.1gをクロロホルム30ml
に溶解した溶液をさらに氷冷下滴下し3時間反応
させた後、生成したトリエチルアミン塩酸塩を
別し、40℃以下で留去する。次いで得られたリポ
酸エチルをエタノール200mlに溶解し、これに氷
冷化において、16gの水素化硼素ナトリウムをエ
タノール100mlに溶解した溶液を滴下しながら1
時間撹拌反応させ、次いで希酢酸で中和後、酢酸
エチルで抽出し、水洗後、溶媒を減圧留去し、ジ
ヒドロリポ酸エチルエステルを得る。これをベン
ゼン200mlに溶解し、さらにトリエチルアミン
32gを加えた混合液にオクチル酸クロライド36g
を氷冷下において滴下しながら1時間撹拌反応さ
せ、次いで室温で2時間撹拌後、反応を停止し、
未反応トリエチルアミンを2%塩酸で処理後、反
応物を酢酸エチルで抽出し、抽出溶媒を留去し粗
反応物を得た。精製はカラムを用いヘキサン/エ
ーテル(98/2)溶媒により溶出させ、無色液体
のS・S―ジオクタノイルリポ酸エチルエステル
30gを得る。収率61%
元素分析
実測値 C:64.35% H:9.28% O:12.96%
(計算値 C:63.93% H:9.84% O:13.11%)
合成例3 S・S―ジ―2―エチルヘキサノイル
リポ酸―2―エチルヘキシルエステル
α―リポ酸20.6gとトリエチルアミン10.1gをベ
ンゼン100mlに溶解した混合液に、別に新しく蒸
溜した塩化チオン11.9gをベンゼン30mlに溶解し
たものを、氷冷下において滴下しながら1時間撹
拌反応させ、生成するα―リポ酸クロライドを取
り出すことなく、2―エチルヘキシルアルコール
12g、トリエチルアミン10.1gをベンゼン30mlに溶
解した混合液をさらに氷冷下滴下し3時間反応さ
せた後、生成したトリエチルアミン塩酸塩を別
し、溶媒を40℃以下で留去する。次いで得られた
リポ酸―2―エチルヘキシルエステルをテトラヒ
ドロフランス200mlに溶解し、これに氷冷下にお
いて16gの水素化硼素ナトリウムをテトラヒドロ
フランに分散した溶液を滴下しながら1時間撹拌
反応させ、次いで希酢酸で中和後酢酸エチルで抽
出し、水洗後、溶媒を減圧留去し、ジヒドロリポ
酸α―エチルヘキシルエステルを得る。これをベ
ンゼン200mlに溶解し、さらにトリエチルアミン
32gを加えた混合液に、2―エチルヘキサン酸ク
ロライド36gを氷冷下において滴下しながら1時
間撹拌反応させ、次いで室温で2時間撹拌、さら
にベンゼンの沸点で還流を1時間行なつた後、反
応を停止し、未反応トリエチルアミンを2%塩酸
で処理後、反応物を酢酸エチルで抽出し、さらに
抽出溶媒を留去し粗反応物を得た。精製はカラム
を用いヘキサン/エーテル(98/2)溶媒により
溶出させ、無色液体のS・S―ジ―2―エチルヘ
キサノイルリポ酸―2―エチルヘキシルエステル
28gを得る。収率49%
元素分析
実測値 C:67.95% H:10.43% O:10.84%
(計算値 C:67.13% H:10.49% O:11.19%)
本発明化粧料に配合されるS・S―ジアシルリ
ポ酸及びそのアルキルエステル誘導体の配合量は
それぞれ化粧料成分全重量中0.01〜5重量%、好
適には0.1〜1重量%である。0.01重量%以下で
は皮膚に対し本発明化粧料を塗布しても経皮吸収
量が皮膚の黒化を防止する至適量とならず、また
5重量%以上の場合は過度のチロシナーゼ活性阻
害による不自然な脱色効果を皮膚に与えやすいこ
とから、これらの範囲は避けるべきである。
上記本発明に係るジヒドロリポ酸誘導体を化粧
料基剤に配合する場合には、これらを単独である
いは併用しても、またその他の還元性物質と共に
用いてもよい。ただ本物質そのものは油溶性であ
り、これまで提供されている、チロシナーゼ阻害
物質よりも油剤その他の有機溶剤に対する溶解性
は頗るよいため、これら従来物質よりも有利に使
用される。すなわち、本発明において主要な点の
一つは、溶解性の向上と実際の系での安定性に留
意して、ジヒドロリポ酸に由来する効果を充分に
発揮させるために、ジヒドロリポ酸の誘導体化を
図つたことにある。
S・S―ジアシルリポ酸ならびにそのアルキル
エステル誘導体の一つであるS・S―ジオクタノ
イルリポ酸エチルエステルのチロシナーゼ阻害作
用について、ハーデイング―パツセイ(Harding
―Passay)マウスメラノーマから抽出した酵素
チロシナーゼを使用し、その酵素活性をドーパー
クロームの475nmの吸光度を測定するフオトメト
リー法で行なつた。試験物質ジヒドロリポ酸誘導
体の1×10-4molとモルモツト皮膚ホモジネート
とをインキユーベーシヨンした反応液を対照にと
つて反応させると、反応速度は、リポ酸が反応初
速度の9%阻害を示したのに対し、ジヒドロリポ
酸誘導体は30%の阻害を示した。
これより、本発明の適用物質であるジヒドロリ
ポ酸誘導体がチロシナーゼ活性を阻害し、ドーパ
クロームの生成を低下させることが実証された。
次に、本発明品および対照品における美白効果
についての試験結果を表に示す。
試験は色黒、シミ、ソバカスに悩む28〜52才の
女性48名をA,B,C,Dの4グループに分け、
Aグループには本発明品である後記実施例3に係
るクリームを、Bグループには後記実施例3の処
方中、S・S―ジオクタノイルリポ酸エチルエス
テルの代わりにα―リポ酸を配合して得られたク
リームを、Cグループには後記実施例3の処方
中、S・S―ジオクタノイルリポ酸エチルエステ
ルの代わりに酸化形グルタチオンを配合して得ら
れたクリームを、Dグループには後記実施例3の
処方中、S・S―ジオクタノイルリポ酸エチルエ
ステルを除き同量の水を配合して得られたクリー
ムを、それぞれ1日につき朝、晩の2回、1ケ月
間に亘つて継続して使用させ、色黒、シミ、ソバ
カスの改善状態の評価をアンケート調査した。
The present invention provides novel cosmetics, more specifically reduced α
- This relates to cosmetics containing a derivative of lipoic acid (dihydrolipoic acid). Conventionally, α-lipoic acid itself has been widely distributed in the animal and plant kingdom in a state bound to proteins, and has been qualitatively detected. In terms of quantity, for example, 3.2 μg/g in animal liver.
(dry weight). When pyruvate enters the TCA cycle in the mitochondrial fraction of mammalian cells, α-lipoic acid is oxidized to acetyl-CoA, carbon dioxide gas, and two hydrogen atoms with the involvement of coenzyme A (hereinafter abbreviated as CoA). In one step, the acyl group is involved in the rearrangement of the acyl group. After the acyl group of α-lipoic acid present in the body is transferred to CoASH, reduced dihydrolipoic acid is formed, but it is reoxidized by lipoic acid dehydrogenase and returns to α-lipoic acid. In this way, α-lipoic acid is a substance that undergoes reversible redox in the living body, and plays an important role in energy production within cells. It can be said that there are no known examples of its application. The reason is,
α-lipoic acid itself is relatively stable in solid form, but when heated above its melting point or in the presence of acid, light, etc., the S-S bond tends to cleave and polymerize, resulting in its stability. This was due to sexual difficulties. As a result of intensive research on the effective use of α-lipoic acid, the present inventor solved the above-mentioned difficulties by derivatizing its reduced form (dihydrolipoic acid), and in addition, when incorporated into a cosmetic base. We have now discovered a cosmetic that has significantly improved effects when applied to the skin, ie, prevents skin darkening, age spots, and freckles due to the inhibition of tyrosinase activity, compared to α-lipoic acid. Generally, when the skin is irradiated with ultraviolet rays from sunlight, tyrosinase activity in the skin causes
Melanin is produced significantly and the skin tends to darken. Ascorbic acids, hydrogen peroxide, glutathione, goroid sulfur, and various other natural products have long been known as substances that prevent this skin blackening phenomenon. In systems containing a large amount, it is easily oxidized and unstable, which tends to cause discoloration and odor. As for hydrogen peroxide, it is difficult to say that it is sufficient in terms of storage and stability due to its characteristics as a peroxide. Glutathione and colloidal sulfur are avoided in cosmetics because they emit a distinct odor. Moreover, there are almost no natural products whose effects have been confirmed, and like the above-mentioned substances, their effects on the skin are not fully satisfactory. That is, the main object of the present invention is to provide a novel cosmetic product that has extremely excellent properties and effects that cannot be obtained with conventionally known substances by incorporating a dihydrolipoic acid derivative into a cosmetic base material. The dihydrolipoic acid derivative applied to the present invention is represented by the following general formula (), in which the 6th and 8th positions are
The mercapto group at position is substituted with various acyl groups, and the carboxyl group is unsubstituted or esterified with various alkyl groups. General formula () (In the formula, R is a linear or branched fatty acid acyl residue, and R' represents either a hydrogen atom or a linear or branched alcohol alkyl residue.) S.S-diacyllipoic acid, which is the dihydrolipoic acid derivative mentioned above. Specific examples of ester derivatives thereof include S.S.-dibutanoyllipoic acid, S.S.-dioctanoyllipoic acid, S.S.-dilauroyllipoic acid, S.S.-dipalmitoyllipoic acid, and S.S.-dibutanoyllipoic acid. -2-ethylhexanoyl lipoic acid, S・S-di-
2-hexyldecanoyllipoic acid, S.S.dioctanoyllipoic acid ethyl ester, S.S.dipalmitoyllipoic acid ethyl ester, S.S.-di-2
-Ethylhexanoyllipoic acid-2-ethylhexyl ester, S.S.-di-2-hexyldecanoyllipoic acid octyldodecyl ester, S.S.-dilauroyllipoic acid cetyl ester, S.S.-dibutanoyllipoic acid 2-hexyldecyl ester Ester, etc., in which the acyl group represented by R in the general formula () has 2 to 20 carbon atoms, and the alkyl group represented by R' has 1 to 20 carbon atoms, are stable and easy to handle in cosmetics. These are listed in terms of ease of application, and are appropriately selected depending on the type of cosmetic preparation. S・S is particularly excellent in terms of stability and effectiveness.
-Dioctanoyllipoic acid ethyl ester, S.S.
- dipalmitoyllipoic acid ethyl ester, etc. There are various methods for synthesizing S.S.-diacyllipoic acid and its alkyl ester derivatives that are applicable to the present invention. For example, in the case of S.S.-diacyllipoic acid, α-lipoic acid is hydrogenated in an appropriate solvent such as ethanol. The disulfide bond is cleaved with a reducing agent such as sodium boron to form dihydrolipoic acid, which is then treated in a non-polar solvent such as tetrahydrofuran.
It is advantageous to obtain the desired product by reacting a desired fatty acid chloride in the presence of a base such as triethylamine, and in the case of S.S-diacyllipoic acid alkyl ester derivatives, α-lipoic acid is first reacted with triethylamine or the like in an appropriate solvent such as chloroform. A chlorinating agent such as thionyl chloride is reacted in the presence of a base to produce α-lipoyl chloride, which is then treated with ethanol,
It is also advantageous to react a desired alcohol such as cetanol in the presence of a base such as triethylamine to form an α-lipoic acid alkyl ester, and then perform disulfide cleavage and acylation to obtain the desired product according to the above-mentioned method. Next, a synthesis example of S.S-diacyllipoic acid and its alkyl ester derivatives will be shown. Synthesis example 1 S.S-dipalmitoyllipoic acid 16g of sodium borohydride and 200ml of ethanol
Dissolve 20.6g of α-lipoic acid in ethanol.
The solution dissolved in 100 ml was stirred and reacted for 1 hour while being added dropwise under ice-cooling. Then, the excess sodium borohydride was neutralized with 5% hydrochloric acid, and the resulting crude product was extracted with ethyl acetate. After washing with water, Solvent at 40℃
Dihydrolipoic acid is obtained by distillation under reduced pressure. This was dissolved in 200 ml of tetrahydrofuran, and 32 g of triethylamine was added thereto. 60 g of palmitic acid chloride was added dropwise under ice-cooling and stirred for 1 hour. Then, after stirring at room temperature for 2 hours, unreacted palmitic acid chloride and triethylamine were added. After treating with ethanol and 2% hydrochloric acid, the reaction product was extracted with ethyl acetate, and the extraction solvent was distilled off to obtain a crude reaction product. For purification, use a column and elute with hexane/ether (98/2) solvent.
45 g of white crystalline S.S-dipalmitoyllipoic acid was obtained. Yield 66% Elemental analysis Actual values C: 70.56% H: 11.02% O: 9.08% (Calculated values C: 70.18% H: 11.11% O: 9.36%) Synthesis example 2 S.S-dioctanoyllipoate ethyl α -To a mixture of 20.6 g of lipoic acid and 10.1 g of triethylamine dissolved in 100 ml of chloroform, separately add 11.9 g of freshly distilled thionyl chloride to 30 g of chloroform.
ml, stirred and reacted for 1 hour while dripping under ice-cooling, 32 g of ethanol was added without taking out the α-lipoyl chloride produced, and 10.1 g of triethylamine was added to 30 ml of chloroform.
The solution dissolved in the solution was further added dropwise under ice-cooling and reacted for 3 hours, and then the triethylamine hydrochloride produced was separated and distilled off at below 40°C. Next, the obtained ethyl lipoate was dissolved in 200 ml of ethanol, and while cooling on ice, a solution of 16 g of sodium borohydride dissolved in 100 ml of ethanol was added dropwise.
The reaction mixture is stirred for a period of time, then neutralized with dilute acetic acid, extracted with ethyl acetate, washed with water, and the solvent is distilled off under reduced pressure to obtain dihydrolipoic acid ethyl ester. Dissolve this in 200ml of benzene and add triethylamine.
36g of octylic acid chloride to the mixture of 32g of
was added dropwise under ice-cooling while stirring for 1 hour, and after stirring at room temperature for 2 hours, the reaction was stopped.
After treating unreacted triethylamine with 2% hydrochloric acid, the reaction product was extracted with ethyl acetate, and the extraction solvent was distilled off to obtain a crude reaction product. Purification was carried out using a column and eluting with hexane/ether (98/2) solvent to obtain colorless liquid S.S-dioctanoyllipoic acid ethyl ester.
Get 30g. Yield 61% Elemental analysis Actual values C: 64.35% H: 9.28% O: 12.96% (Calculated values C: 63.93% H: 9.84% O: 13.11%) Synthesis example 3 S・S-di-2-ethylhexanoyl Lipoic acid-2-ethylhexyl ester To a mixture of 20.6 g of α-lipoic acid and 10.1 g of triethylamine dissolved in 100 ml of benzene, 11.9 g of freshly distilled thione chloride dissolved in 30 ml of benzene was added dropwise under ice cooling. 2-ethylhexyl alcohol without removing the produced α-lipoyl chloride.
A mixture of 12 g of triethylamine and 10.1 g of triethylamine dissolved in 30 ml of benzene was further added dropwise under ice cooling and reacted for 3 hours. The triethylamine hydrochloride formed was separated and the solvent was distilled off at below 40°C. Next, the obtained lipoic acid-2-ethylhexyl ester was dissolved in 200 ml of tetrahydrofuran, and a solution of 16 g of sodium borohydride dispersed in tetrahydrofuran was added dropwise thereto while stirring for 1 hour, followed by dilute acetic acid. After neutralization, the mixture was extracted with ethyl acetate, washed with water, and the solvent was distilled off under reduced pressure to obtain dihydrolipoic acid α-ethylhexyl ester. Dissolve this in 200ml of benzene and add triethylamine.
32g of 2-ethylhexanoyl chloride was added dropwise to the mixture, and 36g of 2-ethylhexanoyl chloride was added dropwise under ice cooling while stirring for 1 hour, followed by stirring at room temperature for 2 hours, and refluxing at the boiling point of benzene for 1 hour. After stopping the reaction and treating unreacted triethylamine with 2% hydrochloric acid, the reaction product was extracted with ethyl acetate, and the extraction solvent was distilled off to obtain a crude reaction product. Purification was carried out using a column and eluting with hexane/ether (98/2) solvent to obtain colorless liquid S.S.-di-2-ethylhexanoyllipoic acid-2-ethylhexyl ester.
Get 28g. Yield 49% Elemental analysis Actual values C: 67.95% H: 10.43% O: 10.84% (Calculated values C: 67.13% H: 10.49% O: 11.19%) S-S-diacyllipoic acid blended into the cosmetic of the present invention The blending amount of the cosmetic composition and its alkyl ester derivative is 0.01 to 5% by weight, preferably 0.1 to 1% by weight, based on the total weight of the cosmetic ingredients. If the amount is less than 0.01% by weight, even if the cosmetic of the present invention is applied to the skin, the amount of transdermal absorption will not be the optimum amount to prevent skin darkening, and if it is more than 5% by weight, there may be problems due to excessive inhibition of tyrosinase activity. These ranges should be avoided as they tend to give the skin a natural bleaching effect. When the dihydrolipoic acid derivatives according to the present invention are incorporated into a cosmetic base, they may be used alone or in combination, or together with other reducing substances. However, this substance itself is oil-soluble and has much better solubility in oils and other organic solvents than the tyrosinase inhibitors provided so far, so it is used more advantageously than these conventional substances. That is, one of the main points of the present invention is to derivatize dihydrolipoic acid in order to fully exhibit the effects derived from dihydrolipoic acid, keeping in mind the improvement of solubility and stability in actual systems. That's what I was trying to do. The tyrosinase inhibitory effect of S.S.-diacyllipoic acid and S.S.-dioctanoyllipoic acid ethyl ester, one of its alkyl ester derivatives, was investigated by Harding-Putsey.
-Passay) Using the enzyme tyrosinase extracted from mouse melanoma, the enzyme activity was measured using a photometry method that measures the absorbance of doperchrome at 475 nm. When a reaction solution prepared by incubating guinea pig skin homogenate with 1×10 -4 mol of the test substance dihydrolipoic acid derivative was reacted as a control, the reaction rate showed that lipoic acid inhibited the initial reaction rate by 9%. In contrast, dihydrolipoic acid derivatives showed 30% inhibition. From this, it was demonstrated that the dihydrolipoic acid derivative, which is an applicable substance of the present invention, inhibits tyrosinase activity and reduces the production of dopachrome. Next, the test results for the whitening effect of the products of the present invention and the control products are shown in the table. For the test, 48 women between the ages of 28 and 52 who suffer from dark skin, age spots, and freckles were divided into four groups: A, B, C, and D.
Group A contained the cream according to Example 3 described below, which is a product of the present invention, and Group B contained α-lipoic acid instead of S.S.-dioctanoyllipoic acid ethyl ester in the formulation of Example 3 described later. The cream obtained by adding oxidized glutathione instead of S.S.-dioctanoyllipoic acid ethyl ester in the formulation of Example 3 described later was added to Group D. A cream obtained by adding the same amount of water except for S.S.-dioctanoyllipoic acid ethyl ester in the formulation of Example 3 below was applied twice a day, once in the morning and once in the evening, for one month. After continuous use, a questionnaire survey was conducted to evaluate the improvement of dark skin, age spots, and freckles.
【表】
表に示された評価によれば、本発明品を使用し
たAグループにおける改善効果が比較品を使用し
たB,C,Dグループに比べて格段に優れている
ことが実証された。
以上詳述した如く、本発明は生体活性に優れた
ジヒドロリポ酸誘導体を効果的に配合した化粧料
に関するものであり、従来知られている各種アス
コルビン酸類、過酸化水素、グルタチオン、コロ
イド硫黄等の皮膚の黒化を防止する物質特にチロ
シナーゼ活性阻害およびメラニン色素脱色作用の
点において同様の作用を有するグルタチオンを配
合した化粧料に比らべ、日光からの紫外線照射に
よつて生じる皮膚の黒化をはるかに防ぐことがで
き、皮膚の色素の色黒やシミ、ソバカスの防止、
美肌効果等の効果が優れていると共に何らの幣害
もなく安全に用いることができるものである。
次に本発明化粧料の実施例を示す。配合割合は
重量部である。
実施例1 パツク
ポリビニルアルコール 20.0
エタノール 20.0
S・S―ジパルミトイルリポ酸エチルエステル
1.0
グリセリン 5.0
香料 適量
水 53.5
実施例2 化粧オイル
スクワラン 49.9
ヒマシ油 49.9
S・S―ジパルミトイルリポ酸 0.5
S・S―ジパルミトイルリポ酸エチルエステル
0.5
ブチルヒドロキシトルエン 0.01
香 料 適量
実施例3 クリーム
ステアリン酸 8.0
鯨ロウ 4.0
セタノール 4.0
ラノリン 2.0
ミリスチン酸イソプロピル 6.0
スクワラン 7.0
オリーブ油 2.0
モノステアリン酸ポリオキシエチレンソルビタ
ン 5.0
モノステアリン酸ソルビタン 1.0
プロピレングリコール 5.0
ブチルパラベン 0.1
メチルパラベン 0.1
ブチルヒドロキシトルエン 0.05
香料 適量
水 54.5
S・S―ジオクタノイルリポ酸エチルエステル
1.0
実施例4 化粧水
エタノール 10.0
プロピレングリコール 5.0
ポリオキシエチレン(50)水添ヒマシ油 0.5
クエン酸 0.015
クエン酸ナトリウム 0.1
メチルパラベン 0.05
S・S―ジブタノイルリポ酸 1.0
香 料 適量
水 83.0[Table] According to the evaluation shown in the table, it was demonstrated that the improvement effect in Group A using the product of the present invention was significantly superior to Groups B, C, and D using comparative products. As detailed above, the present invention relates to cosmetics that effectively contain dihydrolipoic acid derivatives with excellent biological activity, and includes various conventionally known ascorbic acids, hydrogen peroxide, glutathione, colloidal sulfur, etc. Compared to cosmetics containing glutathione, which has similar effects in terms of inhibiting tyrosinase activity and depigmenting melanin pigments, it is far more effective at preventing skin darkening caused by ultraviolet rays from sunlight. It can prevent dark skin pigmentation, dark spots, and freckles,
It has excellent effects such as beautifying the skin and can be used safely without any harm. Next, examples of the cosmetics of the present invention will be shown. The blending ratio is in parts by weight. Example 1 Packed polyvinyl alcohol 20.0 Ethanol 20.0 S・S-dipalmitoyl lipoic acid ethyl ester
1.0 Glycerin 5.0 Fragrance Appropriate amount of water 53.5 Example 2 Cosmetic oil squalane 49.9 Castor oil 49.9 S・S-dipalmitoyllipoic acid 0.5 S・S-dipalmitoyllipoic acid ethyl ester
0.5 Butylated hydroxytoluene 0.01 Fragrance Appropriate amount Example 3 Cream stearic acid 8.0 spermaceti 4.0 cetanol 4.0 lanolin 2.0 isopropyl myristate 6.0 squalane 7.0 olive oil 2.0 polyoxyethylene sorbitan monostearate 5.0 sorbitan monostearate 1.0 propylene glycol 5.0 butyl paraben 0 .1 Methylparaben 0.1 Butylated hydroxytoluene 0.05 Fragrance Appropriate amount of water 54.5 S・S-dioctanoyl lipoic acid ethyl ester
1.0 Example 4 Lotion ethanol 10.0 Propylene glycol 5.0 Polyoxyethylene (50) Hydrogenated castor oil 0.5 Citric acid 0.015 Sodium citrate 0.1 Methylparaben 0.05 S・S-dibutanoyllipoic acid 1.0 Fragrance Appropriate amount of water 83.0
Claims (1)
あり、R′は水素原子又は直鎖、分岐アルコール
アルキル残基のいずれかを表わす。) で示されるS・S―ジアシルリポ酸及びそのアル
キルエステル誘導体のうち少なくとも一種あるい
は二種以上を配合することを特徴とする化粧料。[Claims] 1 General formula () (In the formula, R is a straight chain or branched fatty acid acyl residue, and R' represents either a hydrogen atom or a straight chain or branched alcohol alkyl residue.) A cosmetic comprising at least one or two or more ester derivatives.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP994081A JPS57123107A (en) | 1981-01-26 | 1981-01-26 | Cosmetic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP994081A JPS57123107A (en) | 1981-01-26 | 1981-01-26 | Cosmetic |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57123107A JPS57123107A (en) | 1982-07-31 |
JPH0128002B2 true JPH0128002B2 (en) | 1989-05-31 |
Family
ID=11734004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP994081A Granted JPS57123107A (en) | 1981-01-26 | 1981-01-26 | Cosmetic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57123107A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2145883A1 (en) * | 1998-10-26 | 2010-01-20 | The Research Foundation Of The State University Of New York | Dibenzyl lipoic acid derivatives and their use in treatment of disease |
JP4849792B2 (en) * | 2004-09-14 | 2012-01-11 | オリザ油化株式会社 | Cosmetic composition |
-
1981
- 1981-01-26 JP JP994081A patent/JPS57123107A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS57123107A (en) | 1982-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5857307A (en) | Cosmetic | |
US4959393A (en) | Skin depigmental agent | |
JP3139843B2 (en) | A skin or cosmetic composition having a decolorizing effect, comprising a (2,5-dihydroxyphenyl) carboxylic acid derivative, a homolog or a salt thereof as an active ingredient. | |
LU86258A1 (en) | BENZAMIDO AROMATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | |
JPS6344123B2 (en) | ||
JPH0329057B2 (en) | ||
JPH04244042A (en) | Cosmetic composition | |
US4978523A (en) | Melanin inhibitor | |
WO1997033881A1 (en) | Bicyclic-aromatic compounds | |
IL44742A (en) | Acylamino acid amides their preparation and compositions containing them | |
JPS5946926B2 (en) | Base for cosmetics | |
US6077503A (en) | Skin whitener composition containing mercaptodextran | |
FR2596050A1 (en) | NOVEL BENZOFURAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND DRUG AND COSMETIC COMPOSITIONS CONTAINING SAME | |
FR2764604A1 (en) | BI-AROMATIC COMPOUNDS LINKED BY A PROPYNYLENE OR ALLENYLENE RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | |
US7163673B2 (en) | Sunscreen reagents from hydroxy-substituted acylglycerides | |
FR2649977A1 (en) | BI-AROMATIC ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND COSMETICS | |
IE54244B1 (en) | Cosmetic hair-care and skin-care compositions | |
JPH0128002B2 (en) | ||
JPH0532531A (en) | Cosmetic | |
JPS6320205B2 (en) | ||
CA2075926C (en) | Hydroquinone amino-acid esters, method of preparation, and pharmaceutical or cosmetic compositions containing them | |
JP2663136B2 (en) | Whitening cosmetics | |
JPH0114202B2 (en) | ||
US4898883A (en) | 1-Substituted derivatives of 4-methoxy-2,3,6-trimethylbenzene, process for their preparation and medicinal and cosmetic compositions containing them | |
JP3616668B2 (en) | Photo-aging inhibitor and skin cosmetic comprising the same |